INFU InfuSystem Holdings, Inc
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1337013 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.4%
TTM net income YoY70.9%
TTM EPS YoY69.2%
Revenue 3-yr CAGR5.5%
Net income 3-yr CAGR118.3%
Margins
Gross margin57.6%
Operating margin9.8%
Net margin6.5%
FCF margin17.1%
EBITDA margin18.8%
Returns
ROE15.8%
ROA9.3%
ROIC (approx.)13.4%
Asset turnover1.42x
Leverage & solvency
Liabilities / assets38.6%
Debt / equity0.31x
Current ratio2.68x
Interest coverage13.83x
Cash quality & payout
Operating cash flow / net income2.67x
Accruals ratio-15.5%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $143.44M | $134.86M |
| Cost of revenue | $63.14M | $64.46M |
| Gross profit | $80.30M | $70.40M |
| SG&A expense | $56.97M | $51.21M |
| Operating income | $11.92M | $6.89M |
| Interest expense | $1.30M | $1.78M |
| Pretax income | $10.62M | $5.06M |
| Income tax | $4.00M | $2.71M |
| Net income | $6.63M | $2.35M |
| EBITDA | $25.21M | $19.39M |
| EPS (basic) | 0.32 | 0.11 |
| EPS (diluted) | 0.31 | 0.11 |
| Weighted avg. shares (diluted) | 21.10M | 21.71M |
| Balance sheet | ||
| Cash & equivalents | $3.19M | $527,000 |
| Receivables | $22.90M | $21.20M |
| Inventory | $5.39M | $6.53M |
| Current assets | $36.34M | $32.16M |
| PP&E, net | $3.36M | $4.03M |
| Goodwill | $3.71M | $3.71M |
| Intangibles | $6.87M | $6.46M |
| Total assets | $100.56M | $103.61M |
| Current liabilities | $20.18M | $17.66M |
| Short-term debt | $0 | $0 |
| Long-term debt | $19.62M | $23.86M |
| Total debt | $19.62M | $23.86M |
| Total liabilities | $43.23M | $46.09M |
| Shareholders' equity | $57.33M | $57.53M |
| Net debt | $16.44M | $23.34M |
| Shares outstanding | 20.21M | 21.27M |
| Cash flow statement | ||
| Operating cash flow | $24.41M | $20.46M |
| Capital expenditure | $560,000 | $1.09M |
| Free cash flow | $23.85M | $19.37M |
| Investing cash flow | -$6.79M | -$13.24M |
| Financing cash flow | -$14.96M | -$6.92M |
| Depreciation & amortization | $13.29M | $12.50M |
| Stock-based compensation | $4.36M | $4.46M |
| Share buybacks | $9.87M | $1.18M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.